Title: Peru‘s Dengue Fever Crisis: A Race Against Time and Low Vaccination Rates
In a desperate bid to contain one of the worst dengue fever outbreaks in three decades, Peru has rolled out a vaccination program, but it’s falling short of targets, leaving experts concerned about the country’s ability to handle the surging epidemic.
A Perfect Storm
Peru is grappling with a dengue fever crisis that has already claimed more than 250 lives this year and infected over 270,000 people. The government declared a 90-day health emergency in February, prorogued in May, as cases soared to record levels. The summer months have brought a fresh wave of infections, with over 92,000 new cases reported by mid-November.
The crisis has pushed Peru’s healthcare system to the brink, with services in several regions overwhelmed by patients suffering severe complications. The Pan American Health Organization (PAHO) has warned that the outbreak is a result of inadequate WHO)”>vector control measures and community involvement in prevention efforts.
The Vaccine Dilemma
In response to the escalating crisis, Peru launched a pilot vaccination program on November 23, targeting children, adolescents, and young adults in the most affected regions: Piura, Loreto, Tumbes, and Ucayali. The government secured 445,000 doses of the quadrivalent dengue vaccine, manufactured by Sanofi Pasteur, at a cost of $34 million.
But the program has gotten off to a slow start. By mid-December, less than 11% of the targeted population had received their first dose, leaving health officials worried about the country’s ability to meet its immunization goals. The two-dose vaccine requires a six-month interval between shots, meaning the first cohort won’t be fully protected until late 2025.
The slow rollout comes as the World Health Organization (WHO) emphasizes the importance of integrating vaccination into a comprehensive strategy that includes robust vector control and community engagement. The organization has warned against relying too heavily on vaccination as a standalone solution to the dengue problem.
Challenges on the Ground
In Piura, the initial plan was to vaccinate over 106,000 children between the ages of 10 and 16, with 71 mobile vaccination teams deployed across the region. Similarly ambitious targets were set for the other three regions, but progress has been slow.
Health officials have attributed the sluggish pace to factors such as logistical difficulties, geographically dispersed populations, and resistance to vaccination in some communities. Meanwhile, the disease continues to spread, with cases among adolescents aged 12 to 17 surging in recent months.
The Road Ahead
As the new year begins, Peru faces an uphill battle against dengue fever. The Ministry of Health estimates that the country could see another 290,936 cases in the first half of 2025 alone, driven by factors such as increased rainfall, rising temperatures, and inadequate healthcare preparedness in some regions.
With kuiten of about 2 months remaining to administer the first and second doses to the targeted population, the vaccination campaign must accelerate significantly to make a meaningful impact on the current outbreak. As Delaware’s top public health official, Dr. Karyl Rattray, has noted, the vaccine is just one tool in the fight against dengue, and it must be employed alongside a comprehensive strategy to combat the disease effectively.
